CN119110802A - 中环或大环苄基取代的杂环衍生物和相关用途 - Google Patents

中环或大环苄基取代的杂环衍生物和相关用途 Download PDF

Info

Publication number
CN119110802A
CN119110802A CN202380037293.8A CN202380037293A CN119110802A CN 119110802 A CN119110802 A CN 119110802A CN 202380037293 A CN202380037293 A CN 202380037293A CN 119110802 A CN119110802 A CN 119110802A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
present disclosure
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037293.8A
Other languages
English (en)
Chinese (zh)
Inventor
格雷戈里·R·奥特
K·吉布森
B·莱夫克
P·汉弗莱斯
M·斯彭迪夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sentesa Pharmaceuticals Uk Ltd
Original Assignee
Sentesa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentesa Pharmaceuticals Uk Ltd filed Critical Sentesa Pharmaceuticals Uk Ltd
Publication of CN119110802A publication Critical patent/CN119110802A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202380037293.8A 2022-03-01 2023-03-01 中环或大环苄基取代的杂环衍生物和相关用途 Pending CN119110802A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US63/315,438 2022-03-01
US202363439477P 2023-01-17 2023-01-17
US63/439,477 2023-01-17
PCT/US2023/014275 WO2023167925A1 (en) 2022-03-01 2023-03-01 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Publications (1)

Publication Number Publication Date
CN119110802A true CN119110802A (zh) 2024-12-10

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037293.8A Pending CN119110802A (zh) 2022-03-01 2023-03-01 中环或大环苄基取代的杂环衍生物和相关用途

Country Status (12)

Country Link
US (2) US20250236629A1 (https=)
EP (1) EP4486748A1 (https=)
JP (1) JP2025507852A (https=)
KR (1) KR20240157067A (https=)
CN (1) CN119110802A (https=)
AU (1) AU2023228830A1 (https=)
CA (1) CA3245204A1 (https=)
CL (1) CL2024002576A1 (https=)
IL (1) IL315237A (https=)
MX (1) MX2024010608A (https=)
TW (1) TW202400606A (https=)
WO (1) WO2023167925A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Also Published As

Publication number Publication date
US20250289828A1 (en) 2025-09-18
CL2024002576A1 (es) 2025-01-10
TW202400606A (zh) 2024-01-01
US20250236629A1 (en) 2025-07-24
JP2025507852A (ja) 2025-03-21
IL315237A (en) 2024-10-01
EP4486748A1 (en) 2025-01-08
WO2023167925A1 (en) 2023-09-07
CA3245204A1 (en) 2023-09-07
MX2024010608A (es) 2024-09-23
AU2023228830A1 (en) 2024-09-12
KR20240157067A (ko) 2024-10-31

Similar Documents

Publication Publication Date Title
US12503475B2 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116635393A (zh) 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
CN119110802A (zh) 中环或大环苄基取代的杂环衍生物和相关用途
WO2025072451A1 (en) Ras-pi3k inhibitors for the treatment of cancer and immunological diseases
CN119156375A (zh) 双环杂环衍生物和相关用途
TW202003466A (zh) 人類整合素α４β７拮抗劑
TW201643169A (zh) 作為s1p調節劑的螺-哌啶衍生物
TW202237597A (zh) 新型egfr降解劑
TW202309051A (zh) 食慾素受體促效劑及其用途
TW202417432A (zh) 抗菌化合物
TW201422592A (zh) β－分泌酶抑制劑
CN114761383A (zh) 磺酰胺衍生物及其用途
KR20230083276A (ko) 오토탁신 억제제 화합물
KR102865307B1 (ko) 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도
CN116940562B (zh) 乙酰胺基-苯基苯甲酰胺衍生物及其使用方法
EA052303B1 (ru) Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения
TWI915407B (zh) Ａｐｏｌ１抑制劑及其使用方法
TW202530205A (zh) 經取代之芳基磺醯胺及其組合物及用途
TW202537962A (zh) 抑制α-V β-1整合素
TW202227456A (zh) Ａｐｏｌ１抑制劑及其使用方法
JP2025537242A (ja) 含窒素スピロ環式化合物、医薬組成物及びその用途
HK1184153B (en) Spiro-cyclic amine derivatives as s1p modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination